First-in-mouse testing of your cancer drug candidates - get a quote today!

Having indications from in vitro systems that your drug substance has a potential as a cancer chemotherapeutic or a biologic entity, the next step is to test the drugability in a living organism. We offer a balanced set of in vivo tests to give you a solid base for selecting or de-selecting your drug candidate for further development.

Get a quote: info@pipeline-biotech.dk

Research Pharmacology (DMPK)

- Formulation of dose solution
- Pharmacokinetics (PK)
- Biodistribution (BioD)

Efficacy testing (Xenograft)

- Selection of test system
- Efficacy – inhibition of tumor growth (Xenograft)

Efficacy Testing - the corner stone

Choice of research model is one of the crucial steps for giving a strong selection/deselection answer. We will be your partner and help you choosing a valid xenograft model and can offer different levels of support. Test of treatment efficacy will be xenograft, i.e. immunodeficient mice transplanted with humane cancer cells or patient derived tissue, inoculated s.c., othotopic or i.v. for the disseminated models. The read-outs are tumor growth inhibition and clinical symptoms.



Predictability - what to expect for the clinical phase

Together with Medical Prognosis Institute (MPI) we offer an advanced model selection tool to our European sponsors. MPI's proprietary drug response predictor allows predictions of treatment responses and selection of responding patients, but also to select suited xenograft tumor models. The technology is based on algorithms applied on array data of 10-60 cell lines treated with your drug. With the results of xenograft efficacy data, this will be a powerful tool for prediction of the treatment response in patients.

Does the drug get to the tumor in the living organism



For small chemical entities particular the pharmacokinetic profile is important for planning a dosing schedule securing adequate concentration at the site of the tumors. For the antibody based drugs, biodistribution and specific targeting to the tumor is important for the efficacy of the treatment. We offer a flexible service to determine these parameters and then to enhance the quality of the efficacy testing.

Quality and animal ethics

GLP Compliant since 2003 and GMP Compliant since 2006.
Audited by the Danish Medicines Agency All experiments are conducted in accordance with EU-regulations and approved by the National Animal Experiments Inspectorate. Test animals can be housed at different levels of barrier protection including GMO Class I and Class II and Biohazard Class III.

Pipeline Biotech A/S is an In Vivo CRO providing research pharmacology services for biotech and pharmaceutical companies. We are a dedicated and active partner in drug discovery and pre-clinical development.

Read more about Pipeline Biotech on our homepage: http://www.pipeline-biotech.dk/